Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Annie Guérin
Debbie Goldschmidt
Tania Small
Patrick Gagnon-Sanschagrin
Hela Romdhani
Genevieve Gauthier
Sneha Kelkar
Eric Q. Wu
Polly Niravath
Anand A. Dalal
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
[5] Novartis Pharmaceuticals Corporation,undefined
[6] Analysis Group,undefined
[7] Inc.,undefined
[8] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
CDK4/6 inhibitor; HR+/HER2−; Metastatic breast cancer; Monitoring; Oncology; Post-menopausal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1251 / 1264
页数：13
相关论文
共 50 条
  • [1] Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2-Metastatic Breast Cancer
    Guerin, Annie
    Goldschmidt, Debbie
    Small, Tania
    Gagnon-Sanschagrin, Patrick
    Romdhani, Hela
    Gauthier, Genevieve
    Kelkar, Sneha
    Wu, Eric Q.
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (08) : 1251 - 1264
  • [2] Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Zangardi, Mark L.
    Spring, Laura M.
    Blouin, Gayle C.
    Bardia, Aditya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1169 - 1176
  • [3] Treatment patterns and characteristics of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus.
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] TREATMENT PATTERNS OF ENDOCRINE THERAPY AND CHEMOTHERAPY AMONG POST-MENOPAUSAL WO MEN WITH HR+/HER2-METASTATIC BREAST CANCER
    Lin, P. L.
    Hao, Y.
    Signorovitch, J. E.
    Kelley, C.
    Macalalad, A. R.
    Ohashi, E.
    Zhou, Z.
    Wu, E. Q.
    VALUE IN HEALTH, 2015, 18 (03) : A1221 - A1221
  • [5] Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer
    Anand A. Dalal
    Geneviève Gauthier
    Patrick Gagnon-Sanschagrin
    Rebecca Burne
    Annie Guérin
    Polly Niravath
    Tania Small
    Advances in Therapy, 2018, 35 : 1356 - 1367
  • [6] COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY
    Altundag, K.
    Basaran, G.
    Oksuzoglu, B.
    Oven, B.
    Ozguroglu, M.
    Aydin, D.
    Hacibedel, B.
    Helvacioglu, K.
    Tuna, E.
    Tatar, M.
    VALUE IN HEALTH, 2016, 19 (03) : A146 - A146
  • [7] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer
    Connie Kang
    Targeted Oncology, 2024, 19 : 289 - 296
  • [8] Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2-metastatic breast cancer: a retrospective US claims study
    Guerin, Annie
    Hao, Yanni
    Tang, Derek
    Peeples, Miranda
    Fang, Anna
    Kageleiry, Andrew
    Koo, Valerie
    Li, Nanxin
    Wu, Eric Q.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (09) : 1189 - 1196
  • [9] Ribociclib effective in HR+, HER2– breast cancer
    Sidaway P.
    Nature Reviews Clinical Oncology, 2018, 15 (9) : 532 - 532
  • [10] OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH 1ST-LINE ENDOCRINE THERAPY VS. CHEMOTHERAPY
    Vekeman, F.
    Hao, Y.
    Cheng, W. Y.
    Fortier, J.
    Robitaille, M.
    Duh, M. S.
    VALUE IN HEALTH, 2015, 18 (03) : A194 - A195
12345